Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avaxim Dosing in Immunosuppressed Adolescents
NCT02917577Completed
- Sponsor
- University of Calgary
- Start
- Nov 2016
- Primary completion
- Jun 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Randomised, double-blind trial of Avaxim Junior in hepatitis A (HAV) (2 arms), sponsored by University of Calgary. Primary endpoint: Hepatitis A Antibodies Titre at 7 months. Started Nov 2016; status: completed.
02
Drugs
Avaxim Junior
03
Conditions
hepatitis A (HAV)
Beyond the preview
Go deeper on NCT02917577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02917577.